nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Etoposide—uterine cancer	0.541	1	CbGbCtD
Dolutegravir—Musculoskeletal disorder—Progesterone—uterine cancer	0.0198	0.0547	CcSEcCtD
Dolutegravir—POU2F2—decidua—uterine cancer	0.0167	0.405	CbGeAlD
Dolutegravir—Rash generalised—Progesterone—uterine cancer	0.0166	0.046	CcSEcCtD
Dolutegravir—Rash generalised—Medroxyprogesterone Acetate—uterine cancer	0.0151	0.0417	CcSEcCtD
Dolutegravir—POU2F2—female gonad—uterine cancer	0.0119	0.289	CbGeAlD
Dolutegravir—Bilirubin total increased—Epirubicin—uterine cancer	0.0101	0.0279	CcSEcCtD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—uterine cancer	0.0101	0.182	CbGpPWpGaD
Dolutegravir—Bilirubin total increased—Doxorubicin—uterine cancer	0.00935	0.0258	CcSEcCtD
Dolutegravir—POU2F2—lymph node—uterine cancer	0.00768	0.186	CbGeAlD
Dolutegravir—Opportunistic infection—Epirubicin—uterine cancer	0.00503	0.0139	CcSEcCtD
Dolutegravir—UGT1A1—renal system—uterine cancer	0.00494	0.12	CbGeAlD
Dolutegravir—Opportunistic infection—Doxorubicin—uterine cancer	0.00466	0.0129	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Progesterone—uterine cancer	0.00453	0.0125	CcSEcCtD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—uterine cancer	0.00452	0.0815	CbGpPWpGaD
Dolutegravir—Blood creatinine increased—Medroxyprogesterone Acetate—uterine cancer	0.00436	0.012	CcSEcCtD
Dolutegravir—Abdominal discomfort—Progesterone—uterine cancer	0.00425	0.0118	CcSEcCtD
Dolutegravir—Myositis—Epirubicin—uterine cancer	0.00413	0.0114	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Medroxyprogesterone Acetate—uterine cancer	0.0041	0.0113	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.00403	0.0726	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Progesterone—uterine cancer	0.004	0.0111	CcSEcCtD
Dolutegravir—Abdominal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00385	0.0107	CcSEcCtD
Dolutegravir—Myositis—Doxorubicin—uterine cancer	0.00383	0.0106	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Progesterone—uterine cancer	0.00374	0.0103	CcSEcCtD
Dolutegravir—Inflammation—Etoposide—uterine cancer	0.00373	0.0103	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.00372	0.067	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00363	0.01	CcSEcCtD
Dolutegravir—Hepatitis—Progesterone—uterine cancer	0.00355	0.00981	CcSEcCtD
Dolutegravir—Urinary tract disorder—Progesterone—uterine cancer	0.00351	0.00969	CcSEcCtD
Dolutegravir—Urethral disorder—Progesterone—uterine cancer	0.00348	0.00962	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.00339	0.00937	CcSEcCtD
Dolutegravir—Serum creatinine increased—Epirubicin—uterine cancer	0.0033	0.00911	CcSEcCtD
Dolutegravir—Rash maculo-papular—Etoposide—uterine cancer	0.00329	0.00909	CcSEcCtD
Dolutegravir—Hepatitis—Medroxyprogesterone Acetate—uterine cancer	0.00322	0.00889	CcSEcCtD
Dolutegravir—Immune system disorder—Progesterone—uterine cancer	0.00321	0.00886	CcSEcCtD
Dolutegravir—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.00318	0.00878	CcSEcCtD
Dolutegravir—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.00315	0.00872	CcSEcCtD
Dolutegravir—Mental disorder—Progesterone—uterine cancer	0.00311	0.0086	CcSEcCtD
Dolutegravir—Serum creatinine increased—Doxorubicin—uterine cancer	0.00305	0.00843	CcSEcCtD
Dolutegravir—Flatulence—Progesterone—uterine cancer	0.00305	0.00842	CcSEcCtD
Dolutegravir—Neutropenia—Dactinomycin—uterine cancer	0.00293	0.0081	CcSEcCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—FGFR2—uterine cancer	0.00291	0.0524	CbGpPWpGaD
Dolutegravir—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00291	0.00803	CcSEcCtD
Dolutegravir—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.00282	0.00779	CcSEcCtD
Dolutegravir—Vertigo—Progesterone—uterine cancer	0.00278	0.00767	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—uterine cancer	0.00278	0.05	CbGpPWpGaD
Dolutegravir—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.00276	0.00763	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00261	0.00722	CcSEcCtD
Dolutegravir—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00252	0.00695	CcSEcCtD
Dolutegravir—Hepatitis—Dactinomycin—uterine cancer	0.00251	0.00694	CcSEcCtD
Dolutegravir—Nervous system disorder—Progesterone—uterine cancer	0.00247	0.00684	CcSEcCtD
Dolutegravir—Skin disorder—Progesterone—uterine cancer	0.00245	0.00677	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00237	0.00654	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Etoposide—uterine cancer	0.00232	0.0064	CcSEcCtD
Dolutegravir—Insomnia—Progesterone—uterine cancer	0.00228	0.00631	CcSEcCtD
Dolutegravir—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00224	0.0062	CcSEcCtD
Dolutegravir—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00222	0.00614	CcSEcCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—CCL2—uterine cancer	0.00219	0.0395	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Progesterone—uterine cancer	0.00218	0.00602	CcSEcCtD
Dolutegravir—Fatigue—Progesterone—uterine cancer	0.00218	0.00601	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Epirubicin—uterine cancer	0.00214	0.00592	CcSEcCtD
Dolutegravir—Neutropenia—Etoposide—uterine cancer	0.00212	0.00586	CcSEcCtD
Dolutegravir—Inflammation—Epirubicin—uterine cancer	0.00209	0.00578	CcSEcCtD
Dolutegravir—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00207	0.00571	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Progesterone—uterine cancer	0.00206	0.0057	CcSEcCtD
Dolutegravir—Abnormal dreams—Epirubicin—uterine cancer	0.002	0.00554	CcSEcCtD
Dolutegravir—Abdominal pain—Progesterone—uterine cancer	0.00199	0.00551	CcSEcCtD
Dolutegravir—Renal failure—Etoposide—uterine cancer	0.00199	0.0055	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00199	0.0358	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Doxorubicin—uterine cancer	0.00198	0.00548	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00197	0.00545	CcSEcCtD
Dolutegravir—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00197	0.00545	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—uterine cancer	0.00196	0.0353	CbGpPWpGaD
Dolutegravir—Inflammation—Doxorubicin—uterine cancer	0.00193	0.00535	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Etoposide—uterine cancer	0.00191	0.00529	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00187	0.00517	CcSEcCtD
Dolutegravir—Hypersensitivity—Progesterone—uterine cancer	0.00186	0.00514	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—uterine cancer	0.00185	0.00512	CcSEcCtD
Dolutegravir—Rash maculo-papular—Epirubicin—uterine cancer	0.00184	0.00509	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—uterine cancer	0.00181	0.0326	CbGpPWpGaD
Dolutegravir—Asthenia—Progesterone—uterine cancer	0.00181	0.005	CcSEcCtD
Dolutegravir—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00181	0.00499	CcSEcCtD
Dolutegravir—Urinary tract disorder—Etoposide—uterine cancer	0.00179	0.00496	CcSEcCtD
Dolutegravir—Pruritus—Progesterone—uterine cancer	0.00179	0.00493	CcSEcCtD
Dolutegravir—Urethral disorder—Etoposide—uterine cancer	0.00178	0.00492	CcSEcCtD
Dolutegravir—Diarrhoea—Progesterone—uterine cancer	0.00173	0.00477	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—uterine cancer	0.00171	0.00471	CcSEcCtD
Dolutegravir—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00168	0.00465	CcSEcCtD
Dolutegravir—Dizziness—Progesterone—uterine cancer	0.00167	0.00461	CcSEcCtD
Dolutegravir—Immune system disorder—Etoposide—uterine cancer	0.00164	0.00453	CcSEcCtD
Dolutegravir—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.00453	CcSEcCtD
Dolutegravir—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00447	CcSEcCtD
Dolutegravir—Vomiting—Progesterone—uterine cancer	0.0016	0.00443	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—uterine cancer	0.0016	0.0288	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CTNNB1—uterine cancer	0.0016	0.0288	CbGpPWpGaD
Dolutegravir—Rash—Progesterone—uterine cancer	0.00159	0.0044	CcSEcCtD
Dolutegravir—Dermatitis—Progesterone—uterine cancer	0.00159	0.00439	CcSEcCtD
Dolutegravir—Headache—Progesterone—uterine cancer	0.00158	0.00437	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.00157	0.0283	CbGpPWpGaD
Dolutegravir—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00156	0.00432	CcSEcCtD
Dolutegravir—Renal impairment—Epirubicin—uterine cancer	0.00155	0.00427	CcSEcCtD
Dolutegravir—Fatigue—Dactinomycin—uterine cancer	0.00154	0.00425	CcSEcCtD
Dolutegravir—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00151	0.00418	CcSEcCtD
Dolutegravir—Nausea—Progesterone—uterine cancer	0.0015	0.00414	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00146	0.00403	CcSEcCtD
Dolutegravir—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00145	0.00402	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.00145	0.0261	CbGpPWpGaD
Dolutegravir—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00144	0.00398	CcSEcCtD
Dolutegravir—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00144	0.00398	CcSEcCtD
Dolutegravir—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00143	0.00396	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—uterine cancer	0.00143	0.00395	CcSEcCtD
Dolutegravir—Vertigo—Etoposide—uterine cancer	0.00142	0.00393	CcSEcCtD
Dolutegravir—Abdominal pain—Dactinomycin—uterine cancer	0.00141	0.0039	CcSEcCtD
Dolutegravir—Blood creatinine increased—Epirubicin—uterine cancer	0.00138	0.00381	CcSEcCtD
Dolutegravir—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00136	0.00375	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—EP300—uterine cancer	0.00135	0.0243	CbGpPWpGaD
Dolutegravir—Abdominal pain upper—Epirubicin—uterine cancer	0.00134	0.00372	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00134	0.00369	CcSEcCtD
Dolutegravir—Hypersensitivity—Dactinomycin—uterine cancer	0.00131	0.00363	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.0013	0.00359	CcSEcCtD
Dolutegravir—Asthenia—Dactinomycin—uterine cancer	0.00128	0.00354	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—uterine cancer	0.00128	0.00353	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.00127	0.023	CbGpPWpGaD
Dolutegravir—Skin disorder—Etoposide—uterine cancer	0.00125	0.00346	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—uterine cancer	0.00124	0.00344	CcSEcCtD
Dolutegravir—Diarrhoea—Dactinomycin—uterine cancer	0.00122	0.00337	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.0012	0.00332	CcSEcCtD
Dolutegravir—Neutropenia—Epirubicin—uterine cancer	0.00119	0.00329	CcSEcCtD
Dolutegravir—Hyperglycaemia—Epirubicin—uterine cancer	0.00115	0.00317	CcSEcCtD
Dolutegravir—Vomiting—Dactinomycin—uterine cancer	0.00113	0.00313	CcSEcCtD
Dolutegravir—Rash—Dactinomycin—uterine cancer	0.00112	0.00311	CcSEcCtD
Dolutegravir—Renal failure—Epirubicin—uterine cancer	0.00112	0.00308	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Etoposide—uterine cancer	0.00111	0.00308	CcSEcCtD
Dolutegravir—Fatigue—Etoposide—uterine cancer	0.00111	0.00307	CcSEcCtD
Dolutegravir—Neutropenia—Doxorubicin—uterine cancer	0.0011	0.00304	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.00109	0.0196	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Epirubicin—uterine cancer	0.00107	0.00296	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—uterine cancer	0.00106	0.00293	CcSEcCtD
Dolutegravir—Nausea—Dactinomycin—uterine cancer	0.00106	0.00293	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Etoposide—uterine cancer	0.00106	0.00292	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—uterine cancer	0.00103	0.00285	CcSEcCtD
Dolutegravir—Abdominal pain—Etoposide—uterine cancer	0.00102	0.00282	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—uterine cancer	0.00102	0.00281	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.00101	0.0182	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Epirubicin—uterine cancer	0.00101	0.00278	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—uterine cancer	0.000998	0.00276	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000993	0.00274	CcSEcCtD
Dolutegravir—Hypersensitivity—Etoposide—uterine cancer	0.000951	0.00263	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—uterine cancer	0.000942	0.0026	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—uterine cancer	0.000931	0.00257	CcSEcCtD
Dolutegravir—Asthenia—Etoposide—uterine cancer	0.000926	0.00256	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—uterine cancer	0.000924	0.00255	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—uterine cancer	0.00092	0.00254	CcSEcCtD
Dolutegravir—Pruritus—Etoposide—uterine cancer	0.000913	0.00252	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—uterine cancer	0.000892	0.00247	CcSEcCtD
Dolutegravir—Diarrhoea—Etoposide—uterine cancer	0.000883	0.00244	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—uterine cancer	0.000874	0.00241	CcSEcCtD
Dolutegravir—Dizziness—Etoposide—uterine cancer	0.000854	0.00236	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—uterine cancer	0.000851	0.00235	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—uterine cancer	0.000826	0.00228	CcSEcCtD
Dolutegravir—Vomiting—Etoposide—uterine cancer	0.000821	0.00227	CcSEcCtD
Dolutegravir—Rash—Etoposide—uterine cancer	0.000814	0.00225	CcSEcCtD
Dolutegravir—Dermatitis—Etoposide—uterine cancer	0.000813	0.00225	CcSEcCtD
Dolutegravir—Headache—Etoposide—uterine cancer	0.000809	0.00223	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—uterine cancer	0.000808	0.00223	CcSEcCtD
Dolutegravir—Vertigo—Epirubicin—uterine cancer	0.000796	0.0022	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—NFE2L2—uterine cancer	0.000789	0.0142	CbGpPWpGaD
Dolutegravir—Nausea—Etoposide—uterine cancer	0.000767	0.00212	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GPX3—uterine cancer	0.000753	0.0136	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00075	0.00207	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000742	0.0134	CbGpPWpGaD
Dolutegravir—Vertigo—Doxorubicin—uterine cancer	0.000737	0.00204	CcSEcCtD
Dolutegravir—Nervous system disorder—Epirubicin—uterine cancer	0.00071	0.00196	CcSEcCtD
Dolutegravir—Skin disorder—Epirubicin—uterine cancer	0.000703	0.00194	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000694	0.00192	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—uterine cancer	0.000657	0.00181	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—uterine cancer	0.000654	0.00181	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GPX3—uterine cancer	0.000651	0.0117	CbGpPWpGaD
Dolutegravir—Skin disorder—Doxorubicin—uterine cancer	0.00065	0.0018	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000625	0.00173	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—uterine cancer	0.000624	0.00172	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP11A1—uterine cancer	0.000613	0.0111	CbGpPWpGaD
Dolutegravir—Insomnia—Doxorubicin—uterine cancer	0.000605	0.00167	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP11A1—uterine cancer	0.000605	0.0109	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Epirubicin—uterine cancer	0.000592	0.00163	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000588	0.0106	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000578	0.0016	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—uterine cancer	0.000577	0.00159	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—uterine cancer	0.000572	0.00158	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000571	0.0103	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000547	0.00151	CcSEcCtD
Dolutegravir—Hypersensitivity—Epirubicin—uterine cancer	0.000533	0.00147	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—uterine cancer	0.000529	0.00146	CcSEcCtD
Dolutegravir—Asthenia—Epirubicin—uterine cancer	0.000519	0.00143	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000517	0.00931	CbGpPWpGaD
Dolutegravir—Pruritus—Epirubicin—uterine cancer	0.000512	0.00141	CcSEcCtD
Dolutegravir—Diarrhoea—Epirubicin—uterine cancer	0.000495	0.00137	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—uterine cancer	0.000493	0.00136	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—uterine cancer	0.00048	0.00133	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—uterine cancer	0.000478	0.00132	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—uterine cancer	0.000474	0.00131	CcSEcCtD
Dolutegravir—Vomiting—Epirubicin—uterine cancer	0.00046	0.00127	CcSEcCtD
Dolutegravir—Diarrhoea—Doxorubicin—uterine cancer	0.000458	0.00127	CcSEcCtD
Dolutegravir—Rash—Epirubicin—uterine cancer	0.000456	0.00126	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—uterine cancer	0.000456	0.00126	CcSEcCtD
Dolutegravir—Headache—Epirubicin—uterine cancer	0.000453	0.00125	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP19A1—uterine cancer	0.000451	0.00813	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP19A1—uterine cancer	0.000445	0.00802	CbGpPWpGaD
Dolutegravir—Dizziness—Doxorubicin—uterine cancer	0.000443	0.00122	CcSEcCtD
Dolutegravir—Nausea—Epirubicin—uterine cancer	0.00043	0.00119	CcSEcCtD
Dolutegravir—Vomiting—Doxorubicin—uterine cancer	0.000426	0.00118	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—uterine cancer	0.000422	0.00117	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—uterine cancer	0.000422	0.00117	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—uterine cancer	0.000419	0.00116	CcSEcCtD
Dolutegravir—Nausea—Doxorubicin—uterine cancer	0.000398	0.0011	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—SRD5A2—uterine cancer	0.000242	0.00437	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NDUFB11—uterine cancer	0.000242	0.00437	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKR1B1—uterine cancer	0.000175	0.00316	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—STAR—uterine cancer	0.000175	0.00316	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—POLD1—uterine cancer	0.000138	0.00248	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKR1C1—uterine cancer	0.000129	0.00232	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—RRM2—uterine cancer	0.000115	0.00207	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—DCN—uterine cancer	0.000111	0.00201	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP11A1—uterine cancer	0.000105	0.00189	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKR1C3—uterine cancer	9.91e-05	0.00179	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—STK11—uterine cancer	7.72e-05	0.00139	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP19A1—uterine cancer	7.72e-05	0.00139	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTHFR—uterine cancer	5.8e-05	0.00105	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—uterine cancer	3.23e-05	0.000581	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—EP300—uterine cancer	3.08e-05	0.000554	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—uterine cancer	2.28e-05	0.00041	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—uterine cancer	1.86e-05	0.000335	CbGpPWpGaD
